APA (7th ed.) Citation

Godbert, Y., Cousin, S., Bellera, C., Guégan, J., Hadoux, J., Gomez-Roca, C., . . . Italiano, A. (2024). 1925MO Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC). Annals of Oncology, 35, S1120. https://doi.org/10.1016/j.annonc.2024.08.2006

Chicago Style (17th ed.) Citation

Godbert, Y., et al. "1925MO Regomune Study: A Phase II Study of Regorafenib + Avelumab in Solid Tumors. Results of the Radioiodine-refractory Differentiated Thyroid Cancer (RR-DTC)." Annals of Oncology 35 (2024): S1120. https://doi.org/10.1016/j.annonc.2024.08.2006.

MLA (9th ed.) Citation

Godbert, Y., et al. "1925MO Regomune Study: A Phase II Study of Regorafenib + Avelumab in Solid Tumors. Results of the Radioiodine-refractory Differentiated Thyroid Cancer (RR-DTC)." Annals of Oncology, vol. 35, 2024, p. S1120, https://doi.org/10.1016/j.annonc.2024.08.2006.